Press

The HTGF-portfolio company FIAGON AG SECURES A PATENT LICENSE AGREEMENT WITH GE HEALTHCARE, AND FIAGON AG HAS RECEIVED NOTICE OF 510(k) CLEARANCE FROM THE FDA as well as chinese CFDA approval

June 2, 2014

GE Healthcare and Fiagon AG Announce a Patent License Agreement
Fiagon AG today announced that it has entered into an agreement with GE Healthcare. Under the terms of the agreement, Fiagon will acquire a patent license to several of GE Healthcare’s ENT and Cranial navigation technologies. This will help Fiagon surround and back up the 35 issued patents and substantial intellectual property of Fiagon, resulting in greater protection from competitive interference by other companies.

This agreement is further evidence of Fiagon´s commitment to seek to enhance innovation in surgical navigation and to maintain technological leadership. Recently developed instruments for ENT surgery include the first bendable navigated instrument, the FlexPointer for precise sinus applications and the navigated FinePointer for applications onto the Laterobase. Both products using the Fiagon unique “chip on the tip” technology for navigation.

The GE Healthcare patent license agreement was acquired by Fiagon for an undisclosed cash payment.

Regulatory Approval in the USA and China Fiagon today also announced that it has received US FDA 510(k) clearance on April 30, 2014 to market its proprietary surgical navigation system in the United States. This FDA clearance comes shortly after the recent China CFDA regulatory clearance.  Fiagon is anticipating substantial initial orders for the navigation system through master distributor agreements in China and the USA. The navigated FlexPointer, has been very well received in Europe as an instrument that permits surgical sinus intervention without the need of exchange during the surgery. The Pointer is inserted endoscopically assisted and indicates the current position. The unique FlexPointer is navigated at the tip of the instrument and can be intraoperatively adjusted by bending it.

The navigated FinePointer is designed to support skull base surgery for ENT access. The very thin FinePointer is the navigated at the tip and permits less invasive approaches in keyhole surgery resulting in less pain and more rapid recovery for the patient.

Dr. Timo Krüger, chief executive officer of Fiagon AG, said, “We are excited about the excellent acceptance of our technology in Europe, and are looking forward to the penetration of the USA and China markets in the coming years.  Our patent portfolio has been significantly strengthened by the GE license agreement, and coupled with our regulatory clearance, we are ready to move rapidly to expand our sales to the USA and to China”

Amanda Baccarini, Chief Marketing Officer of GE Healthcare Surgery, said, “At GE Healthcare, we believe in the benefits of surgical navigation and are pleased to license technology to Fiagon AG in order to advance minimally invasive procedures in the ENT and Cranial fields.”

ABOUT FIAGON
Fiagon AG medical technologies, a private investor owned company based in Berlin, Germany, is the parent company of Fiagon GmbH Holding. Fiagon develops and manufactures innovative surgical navigation systems of the latest generation with its proprietary “chip on the tip” technology. In the last 4 years Fiagon, along with world-renowned physicians, has changed the standard in ENT navigation with its proprietary navigation technology.  And this unique technology is expected to also be very useful in oral and maxillofacial surgery, neurosurgery, spine, and dental surgery.

Contact:
Nicolas Bublies
fiagon GmbH
Neuendorfstr. 23b
D 16761 Hennigsdorf (Berlin)
Phone: +49 3302 201 21 27
Fax: +49 3302 201 21 15
nicolas.bublies@fiagon.de
https://www.fiagon.de

About High-Tech Gruenderfonds
High-Tech Gruenderfonds invests in young, high potential high-tech start-ups. The seed financing provided is designed to enable start-ups to take an idea through prototyping and to market launch. Typically, High-Tech Gruenderfonds invests EUR 500,000 in the seed stage, with the potential for up to a total of EUR 2 million per portfolio company in follow-on financing. Investors in this public/private partnership include the Federal Ministry of Economics and Energy, the KfW Banking Group, as well as strategic corporate investors including ALTANA, BASF, Bayer, B. Braun, Robert Bosch, CEWE, Daimler, Deutsche Post DHL, Deutsche Telekom, Evonik, Lanxess, media + more venture Beteiligungs GmbH & Co. KG, METRO, Qiagen, RWE Innogy, SAP, Tengelmann and Carl Zeiss. High-Tech Gruenderfonds has about EUR 576 million under management in two funds (EUR 272 million HTGF I, EUR 304 million HTGF II).

Contact:
High-Tech Gründerfonds Management GmbH
Dr. Bernd Goergen
Investment Director
Schlegelstraße 2
53113 Bonn
Phone: +49 228 823001-00
Fax: +49 228 823000-50
info@htgf.de
www.high-tech-gruenderfonds.de

Stay up to date

Subscribe now and receive the latest press releases on investments and other news from High-Tech Gründerfonds. We inform you about important developments at HTGF and provide you with interesting news from our portfolio. Whether it’s a successful exit, a new exciting investment or HR news – you’ll be the first to know!

More Press posts

Press
25. March 2024

Successful exit for HTGF: Novo Nordisk to acquire Cardior Pharmaceuticals

Novo Nordisk will acquire Cardior for up to 1.025 billion Euros in upfront and potential milestone payments. Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. High-Tech Gründerfonds (HTGF), one of Europe’s leading seed investors, participated in the first financing round in 2017. Bonn, Germany, 25 March 2024 – Novo Nordisk and Cardior Pharmaceuticals today announced that N
 
Press
25. March 2024

Growth push for CI HUB GmbH, Catalyzing Innovation in Content Integration Solutions

Potsdam, 25.03.2024 – Scale Capital, a Danish early stage technology investor with a focus on helping companies accelerate growth in the US market, has announced its investment in CI HUB GmbH, a leading provider of content integration solutions. This significant seven-figure amount from new and existing investors marks a milestone in CI HUB’s journey towards revolutionizing the way corporates and creatives access digital assets and data. CI HUB specializes in developing innovative
 
Press
20. March 2024

graswald.ai raises $3.3M seed round to scale the way brands create 3D content with AI

The Hannover-based start-up has secured seed funding to build Canva for 3D, leveraging generative AI to transform 3D creative processes for 3D product visualisation. Hannover, 20 March 2024 – graswald.ai announced the close of a $3.3 million seed round led by existing investor Lakestar as well as Supernode Global with continued support from existing investor HTGF and further participation from Spatial Computing expert FOV Ventures, Robin Capital, Angel Invest Ventures and Notion Sc